Dose: 1000 to 1000 mg
Single Dose: 1000 (1000)
Frequency: 24 hourly
Route: PO
Instructions: Must not be taken with food. Taken with 10 mg prednisolone.

. It is of Synthetic origin. . The Molecular Weight of Abiraterone acetate is 391.55.

Abiraterone acetate is contraindicated in conditions like Hypersensitivity,Pregnancy.

The severe or irreversible adverse effects of Abiraterone acetate, which give rise to further complications include Hepatotoxicity.Abiraterone acetate produces potentially life-threatening effects which include Cardiac failure, Angina pectoris, CHF, Atrial fibrillation, ejection fraction decreased, left ventricular dysfunction, arrythmia. which are responsible for the discontinuation of Abiraterone acetate therapy.The symptomatic adverse reactions produced by Abiraterone acetate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Peripheral edema, Hypotension, Hypokalemia, Elevated hepatic transaminases, UTI, Hypertension, adrenal insufficiency.

Abiraterone acetate is primarily indicated in conditions like Prostate cancer.

Abiraterone acetate is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementDextromethorphanDextromethorphan is a substrate of CYP2D6. Abiraterone increases the systemic exposure of dextromethorphan by approximately 2.9 fold. The AUC for dextrorphan, the active metabolite of dextromethorphan, increases approximately 33%.KetoconazoleKetoconazole and other liver enzyme inhibitor (e.g clarithromycin, atazanavir, nefazodone, atazanavir, voriconazole) inhibits the metabolism of abiraterone acetate by inhibiting CYP3A4.combination should be avoided or used with caution.Phenytoin (Na)Phenytoin and other liver enzyme inducers (e.g carbamazepine, rifampicin, phenobarbital) accelerates the metabolism of abiraterone acetate by inducing CYP3A4 and thereby lowers the systemic exposure of abiraterone acetate.Combination should be avoided or used with caution.VORICONAZOLEStrong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Use with caution in patients with a history of cardiovascular disease. Before treatment hypertension must be controlled and hypokalemia must be corrected. Use with caution in patients with increase blood pressure or fluid retention, severe or unstable angina pectoris, recent myocardial infarction or ventricular arrythmia and severe renal impairment. Discontinue in severe hepatotoxicity. Decrease bone density may occur so use of glucocorticoid is advised. Patient with lactose intolerance should not take this drug. It is not for use in women with a child bearing potential.